Clinical benefits for older Alzheimer's disease patients

Okayama Late Dementia Study (OLDS)

Kosuke Matsuzono, Toru Yamashita, Yasuyuki Ohta, Nozomi Hishikawa, Kota Sato, Syoichiro Kono, Kentaro Deguchi, Yumiko Nakano, Koji Abe

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background/objective: There are few reports on the effects of anti-Alzheimer's disease (AD) drugs on older AD patients, and possible differences based on gender in a real world setting. Methods: Okayama Late Dementia Study (OLDS) is a retrospective clinical cohort study focusing on older AD patients (n = 373; age≥75 years) treated with monotherapy donepezil (n = 55), galantamine (n = 222), rivastigmine (n = 63), or memantine (n = 33). The patients were evaluated as an entire group and separated by gender, using seven batteries for dementia assessment at baseline and at 3, 6, and 12 months of drug therapy. Results: All four drugs preserved cognitive and affective functions until 12 months, except for Frontal Assessment Battery (FAB) with memantine (∗p <0.05 versus baseline). Donepezil monotherapy significantly improved Hasegawa Dementia Rating Scale-Revised (HDS-R) at 3 months (∗p <0.05), and memantine (3 and 6 months, ∗p <0.05) and rivastigmine (3 months,.∗p <0.01) improved Abe's Behavior and Psychological Symptom of Dementia Score (ABS), respectively. Activities of daily living (ADL) became significantly worse with galantamine at 12 months (∗p <0.05). Male Mini-Mental State Examination scores became worse at 12 months with donepezil (∗p <0.05), as did female Geriatric Depression Scale scores at 6 months (∗p <0.05). Male HDS-R and ABS scores were preserved in the galantamine group until 12 months. Female ABS scores with memantine improved at 6 months (∗p <0.05), while male ADL scores became worse with rivastigmine at 12 months (∗p <0.05). Conclusion: OLDS revealed that anti-AD drugs were effective even for older AD patients, and the clinical benefits of each drug showed a small difference with regard to gender.

Original languageEnglish
Pages (from-to)687-693
Number of pages7
JournalJournal of Alzheimer's Disease
Volume46
Issue number3
DOIs
Publication statusPublished - Jun 25 2015

Fingerprint

Rivastigmine
Memantine
Dementia
Alzheimer Disease
Galantamine
Activities of Daily Living
Pharmaceutical Preparations
Geriatrics
Cognition
Cohort Studies
Depression
Psychology
Drug Therapy
donepezil

Keywords

  • Activities of daily living
  • affective function
  • Alzheimer's disease
  • cognitive function
  • gender difference
  • late elder patients

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Geriatrics and Gerontology
  • Clinical Psychology

Cite this

Clinical benefits for older Alzheimer's disease patients : Okayama Late Dementia Study (OLDS). / Matsuzono, Kosuke; Yamashita, Toru; Ohta, Yasuyuki; Hishikawa, Nozomi; Sato, Kota; Kono, Syoichiro; Deguchi, Kentaro; Nakano, Yumiko; Abe, Koji.

In: Journal of Alzheimer's Disease, Vol. 46, No. 3, 25.06.2015, p. 687-693.

Research output: Contribution to journalArticle

@article{4b468a25c2d942c6a6a3ab251d8ac038,
title = "Clinical benefits for older Alzheimer's disease patients: Okayama Late Dementia Study (OLDS)",
abstract = "Background/objective: There are few reports on the effects of anti-Alzheimer's disease (AD) drugs on older AD patients, and possible differences based on gender in a real world setting. Methods: Okayama Late Dementia Study (OLDS) is a retrospective clinical cohort study focusing on older AD patients (n = 373; age≥75 years) treated with monotherapy donepezil (n = 55), galantamine (n = 222), rivastigmine (n = 63), or memantine (n = 33). The patients were evaluated as an entire group and separated by gender, using seven batteries for dementia assessment at baseline and at 3, 6, and 12 months of drug therapy. Results: All four drugs preserved cognitive and affective functions until 12 months, except for Frontal Assessment Battery (FAB) with memantine (∗p <0.05 versus baseline). Donepezil monotherapy significantly improved Hasegawa Dementia Rating Scale-Revised (HDS-R) at 3 months (∗p <0.05), and memantine (3 and 6 months, ∗p <0.05) and rivastigmine (3 months,.∗p <0.01) improved Abe's Behavior and Psychological Symptom of Dementia Score (ABS), respectively. Activities of daily living (ADL) became significantly worse with galantamine at 12 months (∗p <0.05). Male Mini-Mental State Examination scores became worse at 12 months with donepezil (∗p <0.05), as did female Geriatric Depression Scale scores at 6 months (∗p <0.05). Male HDS-R and ABS scores were preserved in the galantamine group until 12 months. Female ABS scores with memantine improved at 6 months (∗p <0.05), while male ADL scores became worse with rivastigmine at 12 months (∗p <0.05). Conclusion: OLDS revealed that anti-AD drugs were effective even for older AD patients, and the clinical benefits of each drug showed a small difference with regard to gender.",
keywords = "Activities of daily living, affective function, Alzheimer's disease, cognitive function, gender difference, late elder patients",
author = "Kosuke Matsuzono and Toru Yamashita and Yasuyuki Ohta and Nozomi Hishikawa and Kota Sato and Syoichiro Kono and Kentaro Deguchi and Yumiko Nakano and Koji Abe",
year = "2015",
month = "6",
day = "25",
doi = "10.3233/JAD-150175",
language = "English",
volume = "46",
pages = "687--693",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "3",

}

TY - JOUR

T1 - Clinical benefits for older Alzheimer's disease patients

T2 - Okayama Late Dementia Study (OLDS)

AU - Matsuzono, Kosuke

AU - Yamashita, Toru

AU - Ohta, Yasuyuki

AU - Hishikawa, Nozomi

AU - Sato, Kota

AU - Kono, Syoichiro

AU - Deguchi, Kentaro

AU - Nakano, Yumiko

AU - Abe, Koji

PY - 2015/6/25

Y1 - 2015/6/25

N2 - Background/objective: There are few reports on the effects of anti-Alzheimer's disease (AD) drugs on older AD patients, and possible differences based on gender in a real world setting. Methods: Okayama Late Dementia Study (OLDS) is a retrospective clinical cohort study focusing on older AD patients (n = 373; age≥75 years) treated with monotherapy donepezil (n = 55), galantamine (n = 222), rivastigmine (n = 63), or memantine (n = 33). The patients were evaluated as an entire group and separated by gender, using seven batteries for dementia assessment at baseline and at 3, 6, and 12 months of drug therapy. Results: All four drugs preserved cognitive and affective functions until 12 months, except for Frontal Assessment Battery (FAB) with memantine (∗p <0.05 versus baseline). Donepezil monotherapy significantly improved Hasegawa Dementia Rating Scale-Revised (HDS-R) at 3 months (∗p <0.05), and memantine (3 and 6 months, ∗p <0.05) and rivastigmine (3 months,.∗p <0.01) improved Abe's Behavior and Psychological Symptom of Dementia Score (ABS), respectively. Activities of daily living (ADL) became significantly worse with galantamine at 12 months (∗p <0.05). Male Mini-Mental State Examination scores became worse at 12 months with donepezil (∗p <0.05), as did female Geriatric Depression Scale scores at 6 months (∗p <0.05). Male HDS-R and ABS scores were preserved in the galantamine group until 12 months. Female ABS scores with memantine improved at 6 months (∗p <0.05), while male ADL scores became worse with rivastigmine at 12 months (∗p <0.05). Conclusion: OLDS revealed that anti-AD drugs were effective even for older AD patients, and the clinical benefits of each drug showed a small difference with regard to gender.

AB - Background/objective: There are few reports on the effects of anti-Alzheimer's disease (AD) drugs on older AD patients, and possible differences based on gender in a real world setting. Methods: Okayama Late Dementia Study (OLDS) is a retrospective clinical cohort study focusing on older AD patients (n = 373; age≥75 years) treated with monotherapy donepezil (n = 55), galantamine (n = 222), rivastigmine (n = 63), or memantine (n = 33). The patients were evaluated as an entire group and separated by gender, using seven batteries for dementia assessment at baseline and at 3, 6, and 12 months of drug therapy. Results: All four drugs preserved cognitive and affective functions until 12 months, except for Frontal Assessment Battery (FAB) with memantine (∗p <0.05 versus baseline). Donepezil monotherapy significantly improved Hasegawa Dementia Rating Scale-Revised (HDS-R) at 3 months (∗p <0.05), and memantine (3 and 6 months, ∗p <0.05) and rivastigmine (3 months,.∗p <0.01) improved Abe's Behavior and Psychological Symptom of Dementia Score (ABS), respectively. Activities of daily living (ADL) became significantly worse with galantamine at 12 months (∗p <0.05). Male Mini-Mental State Examination scores became worse at 12 months with donepezil (∗p <0.05), as did female Geriatric Depression Scale scores at 6 months (∗p <0.05). Male HDS-R and ABS scores were preserved in the galantamine group until 12 months. Female ABS scores with memantine improved at 6 months (∗p <0.05), while male ADL scores became worse with rivastigmine at 12 months (∗p <0.05). Conclusion: OLDS revealed that anti-AD drugs were effective even for older AD patients, and the clinical benefits of each drug showed a small difference with regard to gender.

KW - Activities of daily living

KW - affective function

KW - Alzheimer's disease

KW - cognitive function

KW - gender difference

KW - late elder patients

UR - http://www.scopus.com/inward/record.url?scp=84934292082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84934292082&partnerID=8YFLogxK

U2 - 10.3233/JAD-150175

DO - 10.3233/JAD-150175

M3 - Article

VL - 46

SP - 687

EP - 693

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 3

ER -